Impact of adverse drug reactions on the outcomes of tuberculosis treatment
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0269765 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Flávia M Sant Anna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program Clinical Research in Infectious Diseases, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio…. Hauptthemen laut MEDLINE: Alcoholism, Tuberculosis, Drug-Related Side Effects and Adverse Reactions, HIV Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brazilian Program of STD-AIDS and Viral Hepatitis, Fundação Oswaldo Cruz, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Background
Adverse drug reactions (ADR) challenge successful anti-tuberculosis treatment (ATT). The aim of this study was to evaluate the impact of ATT-associated ADR and related factors on ATT outcomes.
Methods
A prospective cohort study of persons with tuberculosis (TB) at a referral center in Rio de Janeiro, Brazil, from 2010 to 2016. Baseline information: race, sex, schooling, economic status, tobacco, drugs and alcohol abuse, HIV-infection status and comorbidities were captured during TB screening and diagnosis. Laboratory exams were performed to confirm TB diagnosis and monitor ADRs, favorable (cure and treatment completion) and unfavorable (death, loss to follow up and failure) outcomes were prospectively captured. The Kaplan-Meier curve was used to estimate the probability of ADR-free time. A logistic regression analysis (backward elimination) was performed to identify independent associations with unfavorable outcomes.
Results
550 patients were enrolled, 35.1% were people living with HIV (PLHIV) and ADR occurred in 78.6% of all participants. Smoking (OR: 2.32; 95% CI:1.34–3.99) and illicit-drug use (OR:2.02; 95% CI:1.15–3.55) were independent risk factors for unfavorable outcomes. In PLHIV, alcohol abuse and previous ART use were associated with unfavorable outcomes. In contrast, ADR increased the odds of favorable outcomes in the overall population. PLHIV more frequently experienced grade 3/4-ADR (18.36%), especially “liver and biliary system disorders”. Lower CD4 counts (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Postgraduate Program Clinical Research in Infectious Diseases, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
- Clinical Research Laboratory on Mycobacteria, (LAPCLIN-TB), National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
- School of Medicine, Federal University of Bahia, Salvador, Brazil.
- Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
- Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil.
- Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, Brazil.
ORCID-Profile: Bruno B Andrade, Valeria C Rolla
Förderung
- Brazilian Program of STD-AIDS and Viral Hepatitis
- Fundação Oswaldo Cruz
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Sant Anna, F. M., Araújo-Pereira, M., Schmaltz, C. A. S., Arriaga, M. B., Andrade, B. B., & Rolla, V. C. (2023). Impact of adverse drug reactions on the outcomes of tuberculosis treatment. PLOS ONE. https://doi.org/10.1371/journal.pone.0269765
Vancouver
Sant Anna FM, Araújo-Pereira M, Schmaltz CAS, Arriaga MB, Andrade BB, Rolla VC. Impact of adverse drug reactions on the outcomes of tuberculosis treatment. PLOS ONE. 2023. doi:10.1371/journal.pone.0269765
BibTeX
@article{SantAnna2023,
author = {Sant Anna, Flávia M and Araújo-Pereira, Mariana and Schmaltz, Carolina A S and Arriaga, María B and Andrade, Bruno B and Rolla, Valeria C},
title = {Impact of adverse drug reactions on the outcomes of tuberculosis treatment},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0269765}
}
EUVIMED